Emergent BioSolutions (EBS) Gross Profit (QoQ) (2011 - 2026)
Emergent BioSolutions (EBS) Gross Profit (QoQ) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.64 Bn | 87.78 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.90 Bn | 32.16 Bn | 1.97 Bn |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.98 Bn | 20.83 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.38 Bn | 18.57 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.67 Bn | 12.24 Bn | 785.00 Mn |
| 10 | Emergent BioSolutions | 385.10 Mn | 223.60 Mn | 84.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.82% |
| Dec 31, 2025 | -56.06% |
| Sep 30, 2025 | 96.22% |
| Jun 30, 2025 | -44.65% |
| Mar 31, 2025 | 74.32% |
| Dec 31, 2024 | -55.20% |
| Mar 31, 2024 | 70.27% |
| Dec 31, 2023 | -2.35% |
| Sep 30, 2023 | -36.39% |
| Jun 30, 2023 | 1,192.11% |
| Mar 31, 2023 | -93.00% |
| Dec 31, 2022 | 75.73% |
| Sep 30, 2022 | -43.06% |
| Jun 30, 2022 | -27.48% |
| Mar 31, 2022 | -69.29% |
| Dec 31, 2021 | 193.03% |
| Sep 30, 2021 | -15.71% |
| Jun 30, 2021 | -8.75% |
| Mar 31, 2021 | 184.31% |
| Dec 31, 2020 | -67.99% |